Recombinant Treatment for Hemophilia A Receives FDA Approval

Long-lasting recombinant treatment for hemophilia A, AFSTYLA, has received FDA approval. The new drug, which its manufacturer CSL Behring announced as available today, “offers patients an opportunity for excellent efficacy with a strong safety profile and twice-weekly dosing--potentially helping patients to fit treatment into their active lives,” says Lisa Boggio, Assistant Professor of Internal Medicine, Hematology and Oncology, Clinical Director of the Rush Hemophilia and Thrombophilia Center, and AFFINITY clinical development program study investigator. Read more about AFSTYLA and its approval here.